This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Merck (MRK) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer
by Zacks Equity Research
This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.
Medicare Releases Negotiated Prices on 10 Expensive Drugs
by Sundeep Ganoria
Following negotiations between Medicare and participating drug companies, some of the world's biggest medicines will see price cuts of 38-79%. These lowered prices will be going into effect in 2026.
Pharma Stock Roundup: AZN Gets Approvals for Imfinzi Expanded Use, MRK Inks New Deal
by Kinjel Shah
Merck (MRK) signs a new collaboration with a private drugmaker. AstraZeneca (AZN) gets approvals for expanded use of Imfinzi.
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.
Zacks Investment Ideas feature highlights: Palantir, Morgan Stanley, Merch, Paypal and Meta Platforms
by Zacks Equity Research
Palantir, Morgan Stanley, Merch, Paypal and Meta Platforms are part of the Zacks Investment Ideas article.
Palantir: A Bet on Geopolitical Turmoil & Government Spending
by Andrew Rocco
Palantir is one of the best growth stories on Wall Street. The company should be a big beneficiary of rising geopolitical tensions and rampant government spending.
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
by Zacks Equity Research
Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.
Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View
by Zacks Equity Research
Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.
Case-Shiller Home Prices Tick in Higher
by Zacks Equity Research
Case-Shiller Home Prices Tick in Higher.
Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View
by Zacks Equity Research
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.
Pre-Markets Flat Again Ahead of Fed Report Tomorrow
by Mark Vickery
Market participants not look hungry to act until it understands more about the Fed's thinking.
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merck (MRK) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 5.56% and 1.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Market Awaits JOLTS Numbers Due Tuesday
by Zacks Equity Research
Market Awaits JOLTS Numbers Due Tuesday.
Big Numbers Ahead: Q2 Earnings, Fed Meeting, Jobs Week
by Mark Vickery
Jobs Week, Fed Week and the busiest week of Q2 earnings so far await us.
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
by Kinjel Shah
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
Countdown to Merck (MRK) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
by Zacks Equity Research
AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.